Elucidation of trans-activation mechanism from TRAIL receptor to EGFR

• Project/Area Number: 23590308
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General pharmacology
• Research Institution: Showa University
• Principal Investigator: OHMORI Tohru 昭和大学, 腫瘍分子生物学研究所, 准教授 (10276529)
• Co-Investigator(Kenkyū-buntansha): YAMAOKA Toshimitsu 昭和大学, 腫瘍分子生物学研究所, 講師 (40384359) ; HIROSE Takashi 昭和大学, 内科学講座呼吸器内科学分野, 准教 (40307038)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: EGFR / TRAIL / EGFR-TKI / 薬剤耐性 / crosstalk signal / EGFR阻害剤 / c-MET / MET / FADD

Research Abstract

We established EGFR-TKI-resistant non-small cell lung cancer (NSCLC) cell lines and found that these cell lines acquired collateral sensitivity to Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (about 70 times) as compared with parental cell line. In parental PC-9, anti-tumor effect of TRAIL was restricted, because TRAIL activates not only apoptotic signaling but also anti-apoptotic signaling through Akt/NFkB activation by cross talk signaling from TRAIL receptor to EGFR. In case of the resistant cell lines that overexpressed c-MET, the crosstalk signaling from TRAIL receptor to c-MET was not observed, and TRAIL-mediated Akt/NFkB activation was quite diminished. From these observations, EGFR-TKI/TRAIL combination is thought to be useful therapy for NSCLC.

Research Products

• [Journal Article] Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients : A prospective study (2014)
  • Author(s): Hiroaki Ito, Tohru Ohmori, et al
  • Journal Title: Int J Oncol Volume: 45 Pages: 227-234
• [Journal Article] Prognostic impact of the number of viable circulating (2014)
  • Author(s): Ito H, Ohmori T et al
  • Journal Title: INTERNATIONAL JOURNAL OF ONCOLOGY Volume: in press
  • Peer Reviewed
• [Journal Article] Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer (2012)
  • Author(s): Hirose T, Yamaoka T, Ohmori T. et al
  • Journal Title: Oncol Res Volume: 20(2-3) Pages: 131-137
• [Journal Article] Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease (2012)
  • Author(s): Okuda K, Hirose T, Yamaoka T, Ohmori T. et al
  • Journal Title: Anticancer Res Volume: 32(2) Pages: 5475-5480
• [Journal Article] Application of a qualitative and quantitative real-time polymerase chain reaction method for detecting genetically modified papaya line 55-1 in papaya products (2012)
  • Author(s): Sakai A, Ohmori T, et al
  • Journal Title: J Thorac Oncol Volume: 9 Pages: 1337-1344
• [Journal Article] Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. (2012)
  • Author(s): Hirose T, Murata Y, Oki Y, Sugiyama T, Kusumoto S, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohnishi T, Ohmori T.
  • Journal Title: Oncology Research Volume: 20 Pages: 131-7
  • Peer Reviewed
• [Journal Article] Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. (2012)
  • Author(s): Okuda K, Hirose T, Oki Y, Murata Y, Kusumoto S, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Ohnishi T, Ohmori T.
  • Journal Title: Anticancer Researcg Volume: 32 Pages: 1337-44
  • Peer Reviewed
• [Journal Article] Application of a qualitative and quantitative real-time polymerase chain reaction method for detecting genetically modified papaya line 55-1 in papaya products. (2012)
  • Author(s): Sakai A, Kasahara K, Ohmori T, Kimura H, Sone T, Fujimura M, Nakao S.
  • Journal Title: Journal of Thorac Oncology Volume: 9 Pages: 1337-44
  • Peer Reviewed
• [Journal Article] EGFR阻害剤の耐性とその克服 (The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant Non-small cell lung cancer) (2012)
  • Author(s): 山岡利光, 大森 亨
  • Journal Title: 癌と化学療法 Volume: 39 Pages: 857-862
• [Journal Article] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer (2011)
  • Author(s): Hirose T, Yamaoka T, Ohmori T, et al
  • Journal Title: Lung Cancer Volume: (Epub ahead of print)
• [Journal Article] Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? (2011)
  • Author(s): Hirose T, Yamaoka T, Ohmori T, et al
  • Journal Title: Lung Cancer Volume: 71(2) Pages: 224-228
• [Journal Article] Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer (2011)
  • Author(s): Oki Y, Hirose T, Yamaoka T, Ohmori T, et al
  • Journal Title: Cancer Chemother Pharmacol Volume: 67(4) Pages: 791-797
• [Journal Article] Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer (2011)
  • Author(s): Murata Y, Hirose T, Yamaoka T, Ohmori T, et al
  • Journal Title: Eur J Cancer Volume: 47(9) Pages: 1336-1342
• [Journal Article] Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer (2011)
  • Author(s): Sugiyama T, Hirose T, Yamaoka T, Ohmori T, et al
  • Journal Title: Oncology Volume: 81(3-4) Pages: 273-280
• [Journal Article] Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. (2011)
  • Author(s): Oki Y, Hirose T, Ohmori T et al
  • Journal Title: Cancer Chemother Pharmacol Volume: 67 Pages: 791-7
  • URL: http://www.ncbi.nlm.nih.gov/pubmed/20556612
  • Peer Reviewed
• [Journal Article] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. (2011)
  • Author(s): Hirose T, Ohmori T et al
  • Journal Title: Lung Cancer Volume: 73 Pages: 345-50
  • URL: http://www.ncbi.nlm.nih.gov/pubmed/21277039
  • Peer Reviewed
• [Journal Article] Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. (2011)
  • Author(s): Murata Y, Hirose T, Ohmori T et al
  • Journal Title: Eur J Cancer Volume: 47 Pages: 1336-42
  • URL: http://www.ncbi.nlm.nih.gov/pubmed/21458256
  • Peer Reviewed
• [Journal Article] Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer (2011)
  • Author(s): Sugiyama T, Hirose T, Ohmori T et al
  • Journal Title: Oncology Volume: 81 Pages: 273-80
  • URL: http://www.ncbi.nlm.nih.gov/pubmed/22122886
  • Peer Reviewed
• [Presentation] Contribution of miR-205 in gefitinib-resistant lung cancer cell lines (2014)
  • Author(s): Toshihiro Suzuki, Toshimitsu Yamaoka, Tohru Ohmori, et al
  • Organizer: Annual Meeting 2014
  • Place of Presentation: American Association for Cancer Research SanDiego
• [Presentation] TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice (2014)
  • Author(s): Toshimitsu Yamaoka, Tohru Ohmori, et al
  • Organizer: Annual Meeting 2014
  • Place of Presentation: American Association for Cancer Research SanDiego(#2277)
• [Presentation] Contribution of miR-205 in gefitinib-resistant lung cancer cell lines. (2014)
  • Author(s): Suzuki T, Ohmori T et al
  • Organizer: Annual Meeting 2014, American Association for Cancer Research
  • Place of Presentation: SanDiego, CA
• [Presentation] TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice. (2014)
  • Author(s): Yamaoka T, Ohmori T et al
  • Organizer: Annual Meeting 2014, American Association for Cancer Research
  • Place of Presentation: SanDiego, CA
• [Presentation] Tivantinib shows a synergistic growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein (2014)
  • Author(s): 大森 亨、山岡利光 他
  • Organizer: 第12回日本臨床腫瘍学会学術集会
  • Place of Presentation: 福岡
• [Presentation] 循環癌細胞の個別採取と増幅抽出ゲノムDNAの次世代シークエンサーによる網羅的遺伝子解析 (2013)
  • Author(s): 伊藤寛晃, 大森亨, 他
  • Organizer: 第113回日本外科学会(福岡)
  • Place of Presentation: 京都(ポスターセッション(375)新規治療法開発遺伝子解析)
  • Year and Date: 2013-04-01
• [Presentation] A novel c-MET inhibitor, tivantinib, shows an additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via its recycling pathway (2013)
  • Author(s): Tohru Ohmori, Toshimitsu Yamaoka, Takashi Hirose, et al
  • Organizer: 19^<th> International Charles Heidelberger Symposium on Cancer Research
  • Place of Presentation: 鹿児島(P-04)
• [Presentation] The characteristics of an acquired dual resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR (2013)
  • Author(s): Toshimitsu Yamaoka, Takashi Hirose, Tohru Ohmori et al
  • Organizer: #5648Annual Meeting 2013
  • Place of Presentation: American Association for Cancer Research Washington
• [Presentation] Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer (2013)
  • Author(s): Masanao Nakashima, Takashi Hirose, Toshimitsu Yamaoka, Tohru Ohmori, et al
  • Organizer: 第11回日本臨床腫瘍学会学術集会
  • Place of Presentation: 仙台(P-1413)
• [Presentation] MET高感受性を示すEGFR-TKI耐性PC-9細胞におけるMET阻害剤耐性細胞株の樹立/The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells (2013)
  • Author(s): 山岡利光, 大森亨, 他
  • Organizer: PC-9 cells第72回日本癌学会学術総会
  • Place of Presentation: 横浜(E-2030)
• [Presentation] 表面増強ラマン散乱(SERS)を用いた新しいオミックス解析技術の開発/Novel methodology of integrated omics analysis by using Surface Enhanced Raman Scattering (SERS): A Preliminary Study (2013)
  • Author(s): 伊藤寛晃, 大森亨, 他
  • Organizer: A Preliminary Study第72回日本癌学会学術総会
  • Place of Presentation: 横浜
• [Presentation] The characteristics of an acquired dual resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR. (2013)
  • Author(s): Yamaoka T, Ohmori T et al
  • Organizer: Annual Meeting 2013, American Association for Cancer Research
  • Place of Presentation: Washington, DC
• [Presentation] Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer (2013)
  • Author(s): Nakashima M, Ohmori T et al
  • Organizer: 第11回日本臨床腫瘍学会学術集会
  • Place of Presentation: 仙台
• [Presentation] MET高感受性を示すEGFR-TKI耐性PC-9細胞におけるMET阻害剤耐性細胞株の樹立／The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells (2013)
  • Author(s): 山岡利光、大森 亨 他
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
• [Presentation] 表面増強ラマン散乱（SERS）を用いた新しいオミックス解析技術の開発／Novel methodology of integrated omics analysis by using Surface Enhanced Raman Scattering (SERS): A Preliminary Study (2013)
  • Author(s): 伊藤寛晃、大森 亨 他
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜
• [Presentation] 気道上皮細胞と非小細胞肺癌細胞におけるTACEを介したTNFによるEGFRのトランス活性化機序の検討 (2012)
  • Author(s): 山岡利光, 村廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (日本呼吸器学会誌1巻増刊Page323)
  • Place of Presentation: 神戸
• [Presentation] 高齢者進行非小細胞肺癌のnedaplatin+gemcitabine併用療法の有効性と安全性のレトロスペクティブ検討 (2012)
  • Author(s): 中嶌賢尚, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (日本呼吸器学会誌1巻増刊Page264)
  • Place of Presentation: 神戸
• [Presentation] 切除不能局所進行非小細胞肺癌に対する胸部放射線療法とvinorelbine, carboplatin同時併用第II相試験 (2012)
  • Author(s): 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (日本呼吸器学会誌1巻増刊Page326)
  • Place of Presentation: 神戸
• [Presentation] 当院におけるCOPD合併肺癌手術例に関する検討 (2012)
  • Author(s): 杉山智英, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (日本呼吸器学会誌1巻増刊Page326)
  • Place of Presentation: 神戸
• [Presentation] 糖尿病合併肺癌の現状について (2012)
  • Author(s): 楠本壮二郎, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (日本呼吸器学会誌1巻増刊Page319)
  • Place of Presentation: 神戸
• [Presentation] HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR (2012)
  • Author(s): Tohru Ohmori, Toshimitsu Yamaoka, Takashi Hirose, et al
  • Organizer: Proceedings of American Association for Cancer Research, #1900
  • Place of Presentation: Chicago
• [Presentation] Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution (2012)
  • Author(s): Tohru Ohmori, Toshimitsu Yamaoka, Takashi Hirose, et al
  • Organizer: 103rd Annual Meeting of American Association for Cancer Research
  • Place of Presentation: Chicago
• [Presentation] Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer (2012)
  • Author(s): Tohru Ohmori, Toshimitsu Yamaoka, Takashi Hirose, et al
  • Organizer: Annual Meeting of American Society of Clinical Oncology
  • Place of Presentation: Chicago
• [Presentation] Micro RNAによるゲフィチニブ耐性関連因子の調節 (2012)
  • Author(s): 鈴木俊宏, 大森亨, 他
  • Organizer: 第16回日本がん分子標的治療学会(S2-4)
  • Place of Presentation: 福岡
• [Presentation] Carboplatin+Paclitaxel+ Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺 (2012)
  • Author(s): 白井崇生, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (癌症例肺癌52巻3号Page359-360)
  • Place of Presentation: 岡山
• [Presentation] 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討 (2012)
  • Author(s): 石田博雄, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (日本癌治療学会誌47巻3号Page2134)
  • Place of Presentation: 横浜
• [Presentation] 当院におけるCOPD合併切除不能非小細胞肺癌に関する検討 (2012)
  • Author(s): 杉山智英, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page775)
  • Place of Presentation: 岡山
• [Presentation] 高齢者小細胞肺癌に対する治療成績の検討 (2012)
  • Author(s): 村田泰規, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page637)
  • Place of Presentation: 岡山
• [Presentation] EGFR遺伝子変異陽性肺腺癌患者に対するゲフィチニブとゾレドロン酸併用療法の有用性に関する後方視的解析 (2012)
  • Author(s): 大木康成, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page625)
  • Place of Presentation: 岡山
• [Presentation] FGFR-TKIの再投与の有効性と安全性の検討. (2012)
  • Author(s): 中嶌賢尚, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page621)
  • Place of Presentation: 岡山
• [Presentation] 進行肺大細胞神経内分泌癌と進展型小細胞肺癌に対する化学療法の有効性の比較 (2012)
  • Author(s): 石田博雄, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page598)
  • Place of Presentation: 岡山
• [Presentation] 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討 (2012)
  • Author(s): 石田博雄, 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page586)
  • Place of Presentation: 岡山
• [Presentation] 切除不能局所進行非小細胞肺癌に対する胸部放射線療法とvinorelbine, carboplatin同時併用第II相試験 (2012)
  • Author(s): 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: (肺癌52巻5号Page579)
  • Place of Presentation: 岡山
• [Presentation] 高齢者進行非小細胞肺癌のnedaplatin+gemcitabine併用療法の有効性と安全性のレトロスペクティブ検討 (2012)
  • Author(s): 山岡 利光, 村田 泰規, 大木 康成, 楠本 壮二郎, 杉山 智英, 白井 崇生, 中嶌 賢尚, 奥田 健太郎, 大西 司, 大森 亨, 廣瀬 敬, 足立 満
  • Organizer: 日本呼吸器学会
  • Place of Presentation: 兵庫、神戸
• [Presentation] 切除不能局所進行非小細胞肺癌に対する胸部放射線療法とvinorelbine、carboplatin同時併用第II相試験 (2012)
  • Author(s): 廣瀬 敬, 大木 康成, 村田 泰規, 杉山 智英, 楠本 壮二郎, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨, 足立 満
  • Organizer: 日本呼吸器学会
  • Place of Presentation: 兵庫、神戸
• [Presentation] 当院におけるCOPD合併肺癌手術例に関する検討 (2012)
  • Author(s): 杉山 智英, 廣瀬 敬, 村田 泰規, 大木 康成, 楠本 壮二郎, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 門倉 光隆, 大森 亨, 足立 満
  • Organizer: 日本呼吸器学会
  • Place of Presentation: 兵庫、神戸
• [Presentation] 糖尿病合併肺癌の現状について (2012)
  • Author(s): 楠本 壮二郎, 大木 康成, 村田 泰規, 杉山 智英, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 廣瀬 敬, 大西 司, 大森 亨, 足立 満
  • Organizer: 日本呼吸器学会
  • Place of Presentation: 兵庫、神戸
• [Presentation] HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR (2012)
  • Author(s): Tohru Ohmori, Tsuyoki Kadofuku, Yoko Ichihashi, Toshimitsu Yamaoka, Takashi Hirose, Mitsuru Adachi, Nagahiro Saijo
  • Organizer: 103rd Meeting of American Association for Cancer Research
  • Place of Presentation: Chicago, IL, USA
• [Presentation] Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution (2012)
  • Author(s): Toshimitsu Yamaoka, Mark Frey, D. Brent Polk, Tohru Ohmori et al
  • Organizer: 103rd Meeting of American Association for Cancer Research
  • Place of Presentation: Chicago, IL, USA
• [Presentation] Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer. (2012)
  • Author(s): Takashi Hirose, Hidehiro Noda, Tohru Ohmori et al
  • Organizer: Annual Meeting of American Society of Clinical Oncology 2012
  • Place of Presentation: Chicago, IL, USA
• [Presentation] Micro RNAによるゲフィチニブ耐性関連因子の調節 (2012)
  • Author(s): 鈴木俊宏、入澤 愛、西尾和人、大森 亨、兎川忠靖、櫻庭 仁
  • Organizer: 第16回日本がん分子標的治療学会
  • Place of Presentation: 福岡 北九州
• [Presentation] Carboplatin+Paclitaxel+Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺癌症例 (2012)
  • Author(s): 白井 崇生, 廣瀬 敬, 大木 康成, 村田 泰規, 楠本 壮二郎, 杉山 智英, 石田 博雄, 中嶌 賢尚, 奥田 健太郎, 大西 司, 足立 満, 山岡 利光, 大森 亨
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] 当院におけるCOPD合併切除不能非小細胞肺癌に関する検討 (2012)
  • Author(s): 杉山 智英, 廣瀬 敬, 大木 康成, 村田 泰規, 楠本 壮二郎, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨, 濱田 健司
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] 高齢者小細胞肺癌に対する治療成績の検討 (2012)
  • Author(s): 村田 泰規, 廣瀬 敬, 大木 康成, 杉山 智英, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] EGFR遺伝子変異陽性肺腺癌患者に対するゲフィチニブとゾレドロン酸併用療法の有用性に関する後方視的解析 (2012)
  • Author(s): 大木 康成, 廣瀬 敬, 村田 泰規, 杉山 智英, 楠本 壮二郎, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] FGFR-TKIの再投与の有効性と安全性の検討 (2012)
  • Author(s): 中嶌 賢尚, 大木 康成, 村田 泰規, 石田 孔子, 杉山 智英, 石田 博雄, 白井 崇生, 山岡 利光, 奥田 健太郎, 大森 亨, 大西 司, 廣瀬 敬
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討 (2012)
  • Author(s): 石田 博雄, 大木 康成, 村田 泰規, 石田 孔子, 楠本 壮二郎, 杉山 智英, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨, 廣瀬 敬
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] 切除不能局所進行非小細胞肺癌に対する胸部放射線療法とvinorelbine、carboplatin同時併用第II相試験 (2012)
  • Author(s): 廣瀬 敬, 村田 泰規, 大木 康成, 杉山 智英, 楠本 壮二郎, 石田 博雄, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨
  • Organizer: 第53回日本肺癌学会総会
  • Place of Presentation: 岡山
• [Presentation] 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討 (2012)
  • Author(s): 202. 石田 博雄, 大木 康成, 村田 泰規, 石田 孔子, 楠本 壮二郎, 杉山 智英, 白井 崇生, 中嶌 賢尚, 山岡 利光, 奥田 健太郎, 大西 司, 大森 亨, 廣瀬 敬
  • Organizer: 第50回日本癌治療学会総会
  • Place of Presentation: 神奈川、横浜
• [Presentation] A novel c-MET inhibitor, tivantinib, shows an additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via its recycling pathway (2012)
  • Author(s): 210. Tohru Ohmori, Tomoko Kanome, Toshimitsu Yamaoka, Takashi Hirose, Fumiaki Koizumi, Kazuto Nishio, Shiro Akinaga
  • Organizer: 19th International Charles Heidelberger Symposium on Cancer Research
  • Place of Presentation: 鹿児島
• [Presentation] 気道上皮細胞と肺癌細胞におけるTNFによるEGFRトランス活性化に寄与するリガンドの同定とアポトーシス制御機構 (2011)
  • Author(s): 山岡利光, 大森亨, 廣瀬敬, 他
  • Place of Presentation: 東京(日本呼吸器学会雑誌49巻増刊Page159)
• [Presentation] 発熱性好中球減少症におけるプロカルシトニンの有用性の検討 (2011)
  • Author(s): 杉山智英, 廣瀬敬, 山岡利光, 大森亨, 他
  • Place of Presentation: 東京(日本呼吸器学会雑誌49巻増刊Page162)
• [Presentation] 超高齢者進行非小細胞肺癌の治療の有用性と安全性について (2011)
  • Author(s): 奥田健太郎, 廣瀬敬, 山岡利光, 大森亨, 他
  • Place of Presentation: 東京(日本呼吸器学会雑誌49巻増刊Page294)
• [Presentation] 再発あるいは前治療無効小細胞肺癌(SCLC)に対するamrubicin, carboplatin併用第II相試験 (2011)
  • Author(s): 廣瀬敬, 山岡利光, 大森亨, 他
  • Place of Presentation: 東京(日本呼吸器学会雑誌49巻増刊Page295)
• [Presentation] HSP70 specifically binds to 15 bp deletion mutant EGFR and modulates sensitivity to EGFR-TKI (2011)
  • Author(s): Tsuyoki Kadofuku, Toshimitsu Yamaoka, Takashi Hirose, Tohru Ohmori, et al
  • Place of Presentation: Orland FL, USA(Proceedings of American Association for Cancer Research, Vol. 52 699)
• [Presentation] EGFR-TKI耐性細胞に対するARQ197のMet阻害機構 (2011)
  • Author(s): 大森亨, 山岡利光, 廣瀬敬, 他
  • Organizer: 第15回がん分子標的治療研究会総会
  • Place of Presentation: 東京(ワークショップW6-4)
• [Presentation] HSP70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cell that expressed mutant EGFR (2011)
  • Author(s): Tohru Ohmori, Toshimitsu Yamaoka, Takashi Hirose, et al
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋(English oral session E-1017)
• [Presentation] TNF transactivates phospho-tyrosine 1068 of EGFR through TACE/EGFR-ligand dependent mechanism (2011)
  • Author(s): Toshimitsu Yamaoka, Takashi Hirose, Tohru Ohmori, et al
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋(P-2051)
• [Presentation] Expression study of micro RNA in Gefitinib resistant cell lines (2011)
  • Author(s): Ai Irisawa,, Tohru Ohmori, T et al
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋(P-2095)
• [Presentation] IV期非小細胞肺がんにおける末梢血中がん細胞数(CTC)と抗がん剤治療の効果と予後との関連性 (2011)
  • Author(s): 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (肺癌51巻5号Page421)
  • Place of Presentation: 大阪
• [Presentation] 高齢者進行非小細胞肺癌に対するnedaplatin +gemcitabine併用療法の有効性と安全性の検討 (2011)
  • Author(s): 中嶌賢尚, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (肺癌51巻5号Page486)
  • Place of Presentation: 大阪
• [Presentation] 糖尿病合併肺癌の現状について (2011)
  • Author(s): 楠本壮二郎, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (肺癌51巻5号Page495)
  • Place of Presentation: 大阪
• [Presentation] 当院におけるCOPD合併肺癌手術例に関する検討 (2011)
  • Author(s): 杉山智英, 廣瀬敬, 山岡利光, 大森亨, 他
  • Organizer: (肺癌51巻5号Page516)
  • Place of Presentation: 大阪
• [Presentation] EGFR-TKI耐性細胞に対するARQ197のMet阻害機構 (2011)
  • Author(s): 大森 亨、鹿目知子、et al
  • Organizer: 第15回がん分子標的治療研究会総会
  • Place of Presentation: 東京
• [Presentation] HSP70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cell that expressed mutant EGFR (2011)
  • Author(s): Tohru Ohmori, Tsuyoki Kadofuku et al
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋
• [Presentation] Expression study of micro RNA in Gefitinib resistant cell lines (2011)
  • Author(s): Ai Irisawa, Tohihiro Suzuki, Tohru Ohmori et al
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋
• [Book] 薬剤耐性研究-次世代シークエンサーを用いた抗がん剤感受性予測-(142) (2013)
  • Author(s): 大森亨
  • Total Pages: 52
  • Publisher: 日本医師会雑誌
• [Book] 薬剤耐性とその克服(改訂第3版) (2012)
  • Author(s): 大森亨
  • Publisher: 新臨床腫学
• [Book] EGFR阻害剤の耐性とその克服(The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant Non-small cell lung cancer)(39巻6号) (2012)
  • Author(s): 山岡利光, 大森亨
  • Publisher: 癌と化学療法
• [Book] :新臨床腫瘍学 (改訂第3版)： 薬剤耐性とその克服 (2012)
  • Author(s): 大森 亨 (分担執筆）
  • Total Pages: 4
  • Publisher: 南江堂
• [Remarks] 昭和大学腫瘍分子生物学研究所
  • URL: http://www.showa-oncology.info/research.html